On a late Thursday evening, Celera Corporation (NASDAQ:CRA) and Medical Therapies Limited have announced that they have entered an exclusive license agreement for the use of Medical Therapies’ midkine patent portfolio for the development of novel lung cancer diagnostics. According to the license agreement, Celera will be able to use the Medical Therapies’ midkine patents for the commercialization and development of diagnostic products to address a range of lung cancer related applications which includes risk assessment, differentiation, prognosis, early detection system, disease progression, response to treatment and monitoring of reoccurrence. Celera Corporation and Medical Therapies Limited both are happy about the intellectual property agreement.

Celera Corporation is one of the upcoming healthcare companies that handles personalized disease management products and services and looks after three main segments which

Richard W. Fisher, president and CEO of the Federal Reserve Bank of Dallas,  was once one of the most expressive economist imaginable often using graphic and sensationalist words and expressions to get our attention when describing the ‘nightmarish predicament’ and ‘monstrous challenge’ that has finally engulfed us. It was only a year ago that he warned that a ‘frightful storm is brewing’ – ‘the mother of all financial storms’ – that could well plunge the U.S. government deeper into a ‘fiscal abyss’ causing the country to become submerged in a ‘vast fiscal chasm’. Fisher has not always been so dramatic in spite of saying recently ‘I am a Texan and Texans speak plainly and directly’ and he is not being very direct these days either.

Fisher once was distracted from the truth but today it would seem that he is being compelled to ignore his very own words of warning referring …